StockNews.com Initiates Coverage on IRIDEX (NASDAQ:IRIX)

Equities research analysts at StockNews.com initiated coverage on shares of IRIDEX (NASDAQ:IRIX) in a research note issued on Monday. The brokerage set a “hold” rating on the medical equipment provider’s stock.

IRIDEX Stock Performance

NASDAQ:IRIX opened at $1.01 on Monday. The company has a quick ratio of 0.85, a current ratio of 1.54 and a debt-to-equity ratio of 0.55. The company has a market cap of $16.80 million, a P/E ratio of -1.51 and a beta of 0.94. IRIDEX has a fifty-two week low of $0.96 and a fifty-two week high of $3.65. The firm’s 50 day moving average is $1.49 and its two-hundred day moving average is $1.64.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.